Why Moderna, Inc. (MRNA) stock moved
Moderna, Inc. (MRNA) shares fell 3.8% to $59.49 as of July 21, 2026, a moderate decline from the prior close of $61.82. BestStocks flagged the session as a major change for MRNA. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MRNA fell 3.8% to $59.49
MRNA fell 3.8% in its latest session, moving from $61.82 to $59.49.
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Moderna, Inc. (MRNA) moved +3.74% from $73.80 to $76.56 on 2026-07-09; Moderna, Inc. (MRNA) moved +2.56% from $79.76 to $81.80 on 2026-07-06, reaching a new 30-day high. Weighing against that: Negative session, down 3.8%; Moderna, Inc. (MRNA) moved -7.51% from $68.28 to $63.15 on 2026-07-16. Wall Street's consensus price target sits at $44.11, implying -25.9% downside from $59.49. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 10 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $59.49, down $2.33 (-3.77%) from the previous close of $61.82. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $59.35 and $81.80, and it currently sits about 1% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $44.11, 25.9% below the recent $59.49. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MRNA line up.
The bullish case
- The Street's most bullish target is $77.00 (+29.4%).
- Moderna, Inc. (MRNA) moved +3.74% from $73.80 to $76.56 on 2026-07-09.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $44.11 sits 25.9% below the recent $59.49, so the average target sees limited room to run.
- The most bearish analyst target is $25.00 (-58.0%).
- Negative session, down 3.8%.
- Moderna, Inc. (MRNA) moved -7.51% from $68.28 to $63.15 on 2026-07-16.
- Moderna, Inc. moved -7.06% intraday from $81.80 to $76.03.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MRNA
Frequently asked questions about MRNA
Why did Moderna, Inc. (MRNA) stock move?
MRNA fell 3.8% to $59.49. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock fall?
MRNA lost 3.77% ($2.33) versus the prior close of $61.82, last trading at $59.49 on 0.6× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-07-31 — about 10 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $44.11, about 25.9% below the current $59.49. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 11 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
